# Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge

Source: https://onco.cc/trials/nct04335292/  
OnCo record `nct04335292` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in lung cancer, run by Mark Vincent, now recruiting.

## Summary

Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge is a phase 2, interventional study registered as NCT04335292 by Mark Vincent, with a registry enrolment figure of 200 participants, started 2021-01-06 and due to reach its primary completion in 2026-06-01. Interventions recorded: Osimertinib First-Line; Platinum + Pemetrexed Chemotherapy Second-Line; Osimertinib Third-Line. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: Objective Response Rate according to Response Evaluation Criteria in Solid Tumors version 1.1. Lung eligibility wording from the registry: "* Pathologically proven advanced non-small cell lung cancer (i". Sites: Canada. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: OCELOT
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT04335292
- Phase: 2
- Setting: Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge
- Sponsor: Mark Vincent
- Enrolled: 200

## Sources

- ClinicalTrials.gov NCT04335292: https://clinicaltrials.gov/study/NCT04335292

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04335292.json